Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MIL 62

Next Previous
Search
Drug Profile

MIL 62

Alternative Names: MIL-62

Latest Information Update: 24 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Mabworks Biotech
  • Developer Beijing Mabworks Biotech; InnoCare Pharma
  • Class Antibodies; Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Urologics
  • Mechanism of Action Antibody-dependent cell cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Follicular lymphoma; Marginal zone B-cell lymphoma; Membranous glomerulonephritis; Neuromyelitis optica
  • Phase II/III Systemic lupus erythematosus
  • Phase II Myasthenia gravis
  • Phase I/II Diffuse large B cell lymphoma; Lupus nephritis; Non-Hodgkin's lymphoma
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 24 Aug 2023 Discontinued - Clinical-Phase-Unknown for Chronic lymphocytic leukaemia in China (IV)
  • 27 Jul 2023 Phase-I/II clinical trials in Diffuse large B cell lymphoma (unspecified route) before July 2023 (Beijing Mabworks Biotech pipeline, July 2023)
  • 27 Jul 2023 Phase-I/II clinical trials in Lupus nephritis in China (unspecified route) before July 2023 (Beijing Mabworks Biotech pipeline, July 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top